Table 1. Summary of presented/published clinical trials of ranibizumab standard monthly and variable dosing regimens for exudative age-related macular degeneration. † Theoretical mean number ...

• Compared to human experts, artificial intelligence (AI)-based tests may be comparably accurate at detecting the exudative (or wet) form of age-related macular degeneration (eAMD). • There were no ...

There are two types of macular degeneration: dry (atrophic) and wet (exudative). While both conditions affect your central vision, they can present symptoms differently. Wet AMD is more rare and ...

There are two types of macular degeneration: dry (non-exudative) and wet (exudative). Dry AMD causes a more gradual loss of vision and progresses through stages. Wet AMD is always severe, and the ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration, a new study says.

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Age-related macular degeneration (AMD) is associated with a higher risk for rheumatoid arthritis (RA), according to a study published online Sept. 9 in Scientific Reports. Je Moon Yoon, from ...

CBNS, such as turmeric, are natural anti-inflammatory and antioxidant agents that may confer benefits against AMD.

The study was published Thursday in JAMA Ophthalmology. Advertisement Macular degeneration is the most frequent cause of irreversible vision loss in the developed world. It affects the macula ...

Science Corporation published preliminary data Tuesday from a late stage, multi-center clinical trial of a retina implant that showed promising results. Using this prosthetic, scientists partially ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...